A Destination For Advanced Oncology Treatment
Patients travel from all over the country to the Nancy N. and J.C. Lewis Cancer & Research Pavilion at St. Joseph’s/Candler for the latest in aggressive cancer care. The LCRP has the very latest in advanced technology, which attracts the top specialists. But even more impressive is SJ/C's unique collaborative approach that results in more innovative, customized treatments. It's truly a national destination for cancer care. Learn more about the latest in cancer treatments. >
Selected By The NCI
The LCRP and Northside Hospital Cancer Institute in Atlanta are part of a new National Cancer Institute program that will bring the latest treatments and clinical trials to Georgia. Learn more.
A Team Approach
Our multi-disciplinary teams tackle the more complex cases and provide personalized care. The teams are comprised of physicians with related specialties and support personnel who meet regularly. We cover breast cancer, gastrointestinal cancer, genitourinary (including prostate) cancer, gynecologic cancers, head and neck cancer, neuro-oncology, skin and melanoma and thoracic (lung) cancer.
The Latest Technology
The centerpiece of our technological cancer-fighting arsenal is the CyberKnife, a robotic system that is so accurate it can deliver higher doses of radiation that can result in fewer treatments for the patient. The CyberKnife complements our stable of TrueBeam radiotherapy system for traditional radiation treatments.
The LCRP also has the latest imaging technology as well as mole mapping technology to track changes to your skin that could signify skin cancer or melanoma.
One of the main goals of the National Cancer Institute's Community Oncology Research Program (NCORP) is to expand clinical trials and offer patient access to the latest trials available. The Nancy N. and J.C. Lewis Cancer & Research Pavilion (LCRP) now has greater access to clinical trials, expanded the number of clinical trials available to patients, started participating in early phase clinical trials and increased focus on minority and underserved population participation in clinical trials.